

Antiplatelet Therapy Response Assessment

Rapid.Easy.Proven.




VerifyNow[®] System

Antiplatelet medications are given with the assumption that all patients respond equally, **but they do not.**

Up to 1 in 3 Patients on Antiplatelet Medications May Not Receive the Expected Antiplatelet Effect.^{1,2,3}

VerifyNow is the first rapid, accurate system for measuring individual response to P2Y12 inhibitors. It's an easy, yet precise tool to help guide treatment decisions, allowing clinicians to assess platelet reactivity as a routine component of care for millions of patients receiving antiplatelet agents.


PROVEN
IN OVER 300
PUBLICATIONS



Accu:
metrics[®]

Unsurpassed Innovation in Technology

The VerifyNow System is designed to mimic light transmittance aggregometry (LTA), delivering results that correlate strongly to LTA and VASP in a more convenient and rapid form.^{1,2} The system measures the rate and extent of changes in light transmittance caused by platelets aggregating in whole blood samples.



Low Platelet Reactivity
Blood samples with inhibited platelets produce low levels of light transmittance

Normal Platelet Reactivity
Blood samples containing normally functioning platelets deliver a higher level of light transmittance

Assessing Platelet Reactivity as a Standard Component of Care

As you determine what's best for your practice and patients, consider this:

- Variability in response is an accepted consideration for patients taking clopidogrel
- High platelet reactivity despite clopidogrel treatment has been associated to clinical outcomes
- Five separate guidelines recommend platelet reactivity testing on some patients, including those at high risk (defined as UA/NSTEMI, or after ACS and PCI). These recommendations are from ACCF/AHA, STS, and ESC (European Society of Cardiology).
- Provides valuable information that may impact treatment decisions and reduce 30-day readmissions or pre-surgical length of stay

	VerifyNow PRUtest**	VerifyNow Aspirin Test
Classification	Whole blood, platelet aggregation in the presence of antiplatelet medications	
CLIA Classification	Moderately Complex	Waived
Antiplatelet Medications	P2Y12 inhibitors	Aspirin
Agonists	ADP (with PGE ¹)	Arachidonic acid
Sample	Whole blood in 2mL Greiner partial fill Vacuette® tubes with 3.2% sodium citrate (blue top P/N 454321).	
Time to Results:	3 min runtime *	5 min runtime *
Test Device Storage	2-25°C (36-77°F) (Room temperature)	
Billing and Reimbursement	CPT 85576	CPT 85576 QW
Test Calibration	Factory calibrated	
Instrument Dimensions	9.5W x 9.3D x 6.5H (inches)	
Instrument Weight	4 lb	

**Formerly P2Y12 Test

For information on VerifyNow IIb/IIIa Test, contact your local distributor.

1 Gurbel, P. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(19):1822-34. 2 Krasopoulos, W. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195-8. 3 Steinhubl, S. et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention Results of the GOLD (AU - Assessing Ultegra) multicenter study. Circulation 2001;103(21):1403-1409.

Easy to Run. Easy to Interpret 3 Easy Steps



1 Open cover. When prompted, insert the test device.



2 Insert tube onto the test device needle.



3 Close cover and read results in 2 to 5 minutes.

Intuitive Operation

- Testing can be done in five minutes or less*
- Uses whole blood, closed tube samples with no pipetting or sample preparation
- Replaces more cumbersome and time-consuming methods
- Allows for simplified testing at the point of care or for easy integration into any lab workflow.

* Sample incubation required

Accu
metrics®

3985 Sorrento Valley Boulevard
San Diego, California USA 92121
Toll Free: 800.643.1640

www.accumetrics.com